Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334866 | 1.00 | CHRNA7 (0.35) | CHRNA7METTL3NR3C2KDM1APRCP | |
| SCHEMBL1333855 | 1.00 | CHRNA7 (0.35) | CHRNA7METTL3NR3C2KDM1APRCP | |
| SCHEMBL1334868 | 1.00 | CHRNA7 (0.35) | CHRNA7METTL3NR3C2KDM1APRCP | |
| SCHEMBL1333460 | 1.00 | CHRNA7 (0.35) | CHRNA7METTL3NR3C2KDM1APRCP | |
| SCHEMBL25331397 | 0.83 | MDM2 (0.36) | CHRNA7METTL3KDM1ATDP1DRD2 | |
| SCHEMBL25331754 | 0.83 | MDM2 (0.36) | CHRNA7METTL3KDM1ATDP1DRD2 | |
| SCHEMBL25330400 | 0.83 | MDM2 (0.36) | CHRNA7METTL3KDM1ATDP1DRD2 | |
| SCHEMBL25331394 | 0.83 | MDM2 (0.36) | CHRNA7METTL3KDM1ATDP1DRD2 | |
| SCHEMBL1334838 | 0.82 | SLC6A2 (0.47) | CHRNA7METTL3PRCPSLC6A2ADRA1A | |
| SCHEMBL1334836 | 0.82 | SLC6A2 (0.47) | CHRNA7METTL3PRCPSLC6A2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569310-A1 | MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Pfizer Inc (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | PFIZER INC | 2011-11-17 | — | — | US | disclosed |
| WO-2011141848-A1 | MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | REN, MC2R, NR3C2 | CHRNA7 2166/4885METTL3 707/4885NR3C2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.